Trimethoprim + SulfamethoxazoleThird Party Manufacturing in India

Trimethoprim + Sulfamethoxazole works by exerting a sequential double block on the bacterial metabolic pathway responsible for synthesizing tetrahydrofolic acid. Sulfamethoxazole inhibits the incorporation of para-aminobenzoic acid into dihydrofolic acid, while trimethoprim prevents the subsequent reduction to tetrahydrofolic acid. Unlike single-agent bacteriostatics, this combined synergistic mechanism converts the action into a bactericidal outcome. It is highly effective and well-tolerated against a broad spectrum of gram-positive and gram-negative microbes.

Therapeutic Uses

• Urinary Tract Infections: Treatment of acute, uncomplicated urinary tract infections caused by susceptible organisms.
• Respiratory Infections: Management of acute exacerbations of chronic bronchitis and otitis media.
• Pneumocystis Pneumonia: Treatment and prophylaxis of severe fungal-bacterial respiratory complications.

Why Manufacturers Choose Trimethoprim + Sulfamethoxazole

Trimethoprim + Sulfamethoxazole third party manufacturing in India is highly prioritized by commercial buyers due to its inclusion in vital essential medicines lists worldwide. Our partner facilities rely on specialized fluid bed dryers and high speed compression matrices to process high volume anti-infective demands efficiently. Celesta utilizes a premier network of WHO-GMP certified plants to meet standard pharmacopeial compliance metrics for global export.